C

PriceCadrenal Therapeutics

CVKD

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Historical stock price chart and annual return over the past years

-75%

2 years

% Total

CVKD
-50%

2 years

Annual Return

CVKD